Review: Human guanidinoacetate n-methyl transferase (GAMT) deficiency: A treatable inborn error of metabolism.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search methodology.
What was done
Narrative review describing the creatine biosynthetic pathway, the pathophysiology and clinical presentation of guanidinoacetate N-methyltransferase (GAMT) deficiency, its biochemical diagnostic markers, and dietary treatment approaches.
What was found
The abstract provides no quantitative data. GAMT deficiency causes systemic depletion of creatine/phosphocreatine and accumulation of guanidinoacetate, presenting with absent comprehensible speech development, severe mental retardation, muscular hypotonia, involuntary movements, and refractory seizures. Dietary creatine supplementation alone or combined with arginine restriction provides variable clinical benefit to treated patients, though none return to fully normal development.
Why it matters
This review highlights a treatable inborn error of metabolism where dietary supplementation can mitigate severe neurological symptoms, while acknowledging the limitations of current therapies in achieving complete neurodevelopmental recovery.
Limits
This is a narrative review with no systematic search methodology, meta-analysis, or new primary data. The abstract provides no sample sizes, treatment dosages, patient ages at initiation, or quantitative outcome measures.
Cited by
- contradicts The human body naturally synthesizes 1 to 3 g of creatine per day only in the liver and brain, and stores 95% of total creatine in skeletal muscle.